Poster number


Submitting author

City and Country


Radiation Free Therapy or the INitial treatment of Good prognosis early non-bulky Hodgkin lymphoma, defined by a low Metabolic Tumor Volume and a negative PET-2 - RAFTING Trial.

Andrea Gallamini

Nice, France


ANIMATE: A phase II study of nivolumab in transplant eligible patients with relapsed/refractory classic Hodgkin lymphoma

Stephen Booth

Oxford, UK


Brentuximab Vedotin in Combination with Nivolumab, Doxorubicin, and Dacarbazine in Newly Diagnosed Patients with Advanced Hodgkin Lymphoma (SGN35-027, Trial in Progress)

Ian Flinn

Nashville, TN, USA


The CLL-RT1 trial: A multicenter phase-2 trial of zanubrutinib, a BTK inhibitor, plus tislelizumab, a PD-1 inhibitor, for patients with Richter Transformation

Othman Al-Sawaf

Cologne, Germany


Phase 3 Trial (GCT3013-05) of Epcoritamab Versus Standard of Care in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Catherine Thieblemont

Paris, France


Phase 3 Randomized Study of Loncastuximab Tesirine plus Rituximab versus Immunochemotherapy in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma – LOTIS-5

Carmelo Carlo-Stella

Rozzano (MI), Italy


ESCALADE: A Phase 3 Study of Acalabrutinib in Combination With R-CHOP for Patients ≤65y With Untreated Non-Germinal Center B-Cell–Like Diffuse Large B-Cell Lymphoma

Laurie Sehn

Vancouver, Canada


A Phase III trial of glofitamab plus gemcitabine and oxaliplatin (GemOx) vs rituximab plus GemOx for relapsed/refractory diffuse large B-cell lymphoma

Mark Hertzberg

Sydney, Australia


Brentuximab Vedotin in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) (Trial in Progress)

Nancy Bartlett

St. Louis, MO, USA


Copanlisib in combination with Rituximab-Bendamustine in patients with Relapsed-Refractory DLBCL: a multicentric Phase II trial of the Fondazione Italiana Linfomi

Mattia Novo

Candiolo (TO), Italy


A Phase II Study of Anti-PD-1 Sintilimab in Combination With Chidamide and Azacitidine in Refractory and Relapsed Peripheral T-cell Lymphoma

Zhitao Ying

Beijing, China


An open-label trial of oral CA-4948 an IRAK4 inhibitor combined with ibrutinib in adult patients with relapsed or refractory hematologic malignancies

Erel Joffe

New York, NY, USA


Epstein-Barr virus-drivendiseases: a multinational, multicohort, open-label phase 2 study to assess the efficacy and safety of tabelecleucel using an adaptive study design

Sylvain Choquet

Paris, France


A phase II study of acalabrutinib in combination with R-CHOP chemotherapy prior to autologous stem cell transplantation in previously untreated mantle cell lymphoma

Diego Villa

Vancouver, Canada


First-line ibrutinib + venetoclax treatment for mantle cell lymphoma in older patients or those with TP53 mutation: a new open-label arm of the phase 3 PCYC-1143 SYMPATICO study

Wojciech Jurczak

Krakow, Poland


Three phase 1/2, open-label studies of cereblon E3 ligase modulator (CELMoD)-based regimens in newly diagnosed (ND) or relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL)

Franck Morschhauser

Lille, France


COASTAL: A Phase 3 Study of the PI3Kδ Inhibitor Zandelisib with Rituximab (R) versus Immunochemotherapy in Patients with Relapsed Indolent Non-Hodgkin’s Lymphoma (iNHL)

Wojciech Jurczak

Krakow, Poland


inMIND: A Phase 3 Study of Tafasitamab + Lenalidomide and Rituximab vs Placebo + Lenalidomide and Rituximab for Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Kai Hübel

Cologne, Germany


A Phase 2 Randomized Study of Loncastuximab Tesirine (Lonca) Versus (Vs) Idelalisib in Patients (Pts) with Relapsed or Refractory (R/R) Follicular Lymphoma (FL) – LOTIS-6

Carmelo Carlo-Stella

Rozzano (MI), Italy